Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Purpose: The study investigated the impact of TP53 mutations on the clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced or recurrent non-small-cell lung cancer (NSCLC). Patients and methods: Tissues from 163 NSCLC patients at the Affiliated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Helei, Qin, Kang, Liang, Yu, Zhang, Chuantao, Liu, Dong, Jiang, Haiping, Liu, Kewei, Zhu, Jingjuan, Lv, Hongying, Li, Tianjun, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594053/
https://www.ncbi.nlm.nih.gov/pubmed/31417310
http://dx.doi.org/10.2147/CMAR.S201513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594053/
https://www.ncbi.nlm.nih.gov/pubmed/31417310
http://dx.doi.org/10.2147/CMAR.S201513

Ejemplares similares